Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy.
Overview
- Department of Neuroscience “Rita Levi Montalcini”, University of Turin,Turin, Italy
- Neuroscience Institute Cavalieri Ottolenghi, Orbassano,Turin, Italy
- Human Translational Genomics Group, University Institute of Biotechnology and Biomedicine, Universidad de Valencia,Burjassot, Spain
- Incliva Biomedical Research Institute,Valencia, Spain
- INSERM/UEVE, UMR 861, Université Paris Saclay, CECS/I-STEM, AFM-Telethon, Rue Henri Desbruères, Corbeil-Essonnes, France
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), CB23/07/00005, Carlos III Health Institute,Madrid, Spain
- Experimental and Applied Biomedicine Research Group, Health Sciences Faculty, Universidad Particular Internacional SEK (UISEK), Quito, Ecuador
Abstract
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by Survival Motor Neuron 1 (SMN1) gene mutations, leading to reduced SMN protein levels and progressive motor neuron (MN) degeneration. Although current therapies aim to restore SMN expression, limitations highlight the need for alternative strategies. We investigated haloperidol (HALO), a classical antipsychotic, as a potential therapeutic based on its ability to enhance SMN2 splicing and SMN expression. Using the delta 7 SMA mouse model, we assessed effects of HALO on survival, motor function, neuroprotection, and neuroinflammation, by histological, molecular, and RNA-sequencing analyses of spinal cord and muscle samples. Additionally, we examined patient induced pluripotent stem cell-derived MNs and myotube co-cultures for validation in human cells. HALO increased lifespan and motor performance in mice with SMA, upregulated SMN protein in spinal cord and muscles, reduced MN loss, and attenuated neuroinflammation. Moreover, HALO enhanced neuromuscular junction integrity and muscle trophism, suggesting peripheral benefits. RNA-sequencing analysis revealed extensive splicing changes, including SMN target transcripts, supporting enhanced activity. In human models, HALO improved MN survival and SMN expression, supporting dual SMN-dependent and neuroprotective mechanisms. Given its central nervous system penetrance and clinical approval, HALO emerges as a promising SMA therapy candidate, warranting further dose optimization and validation for translational potential.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- bioproject:PRJNA1251322, at NCBI BioProject; found in “Data availability”
Data availability
All data are available in the main text or Supplementary material. Supplementary Data files 1 and 2 provide complete RNA-seq quantification in spinal cord and quadriceps of treated delta 7 mice, respectively. The RNA-seq datasets generated during this study are publicly available in the NCBI BioProject repository under accession number PRJNA1251322 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 5 keywords, 12 MeSH terms, 2 funders, 65 references.
Cite
This paper
Menduti, G., Perez-Gomez, R., Berenger-Currias, N., Ruatti, C., Espinosa-Espinosa, J., Januel, C., Konieczny, P., Artero, R., Martinat, C., & Boido, M. (2026). Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy. Experimental & molecular medicine, 58(4), 1216-1229. https://
BibTeX
@article{menduti2026halo
author = {Menduti, Giovanna and Perez-Gomez, Raquel and Berenger-Currias, Noémie and Ruatti, Cristina and Espinosa-Espinosa, Jorge and Januel, Camille and Konieczny, Piotr and Artero, Ruben and Martinat, Cecile and Boido, Marina},
title = {{Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy}},
journal = {Experimental \& molecular medicine},
year = {2026},
month = apr,
volume = {58},
number = {4},
pages = {1216--1229},
publisher = {Korean Society for Biochemistry and Molecular Biology},
issn = {1226-3613},
doi = {10.1038/
url = {https://
pmid = {41974892},
pmcid = {PMC13144737}
}
RIS
TY - JOUR
AU - Menduti, Giovanna
AU - Perez-Gomez, Raquel
AU - Berenger-Currias, Noémie
AU - Ruatti, Cristina
AU - Espinosa-Espinosa, Jorge
AU - Januel, Camille
AU - Konieczny, Piotr
AU - Artero, Ruben
AU - Martinat, Cecile
AU - Boido, Marina
TI - Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy
T2 - Experimental & molecular medicine
J2 - Exp Mol Med
PY - 2026
DA - 2026/
VL - 58
IS - 4
SP - 1216
EP - 1229
SN - 1226-3613
PB - Korean Society for Biochemistry and Molecular Biology
DO - 10.1038/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1038/
"type": "article-journal",
"title": "Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy",
"container-title": "Experimental & molecular medicine",
"author": [
{
"family": "Menduti",
"given": "Giovanna"
},
{
"family": "Perez-Gomez",
"given": "Raquel"
},
{
"family": "Berenger-Currias",
"given": "Noémie"
},
{
"family": "Ruatti",
"given": "Cristina"
},
{
"family": "Espinosa-Espinosa",
"given": "Jorge"
},
{
"family": "Januel",
"given": "Camille"
},
{
"family": "Konieczny",
"given": "Piotr"
},
{
"family": "Artero",
"given": "Ruben"
},
{
"family": "Martinat",
"given": "Cecile"
},
{
"family": "Boido",
"given": "Marina"
}
],
"container-title-short":
"volume": "58",
"issue": "4",
"page": "1216-1229",
"DOI": "10.1038/
"PMID": "41974892",
"PMCID": "PMC13144737",
"ISSN": "1226-3613",
"publisher": "Korean Society for Biochemistry and Molecular Biology",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
13
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1007/s00018-022-04450-8
- Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model.Journal: Cellular and molecular life sciences : CMLSIn common: other condition, mouse, 21 references
- [2] doi:10.1016/j.xcrm.2024.101659 [code]
- Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation.Journal: Cell reports. MedicineIn common: other condition, mouse, 8 references
- [3] doi:10.1038/s44321-025-00303-6
- Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy.Journal: EMBO molecular medicineIn common: other condition, mouse, 6 references
- [4] doi:10.1186/s40478-026-02415-7 [code]
- A standardized framework resolves ambiguity in motor neuron loss across neurodegenerative diseases.Journal: Acta neuropathologica communicationsIn common: other condition, mouse, 5 references
- [5] doi:10.1172/jci.insight.158380
- Bap1/
SMN axis in Dpp4+ skeletal muscle mesenchymal cells regulates the neuromuscular system. Journal: JCI insightIn common: mouse, 5 references - [6] doi:10.1186/s13395-022-00305-9
- Mouse models of SMA show divergent patterns of neuronal vulnerability and resilience.Journal: Skeletal muscleIn common: other condition, mouse, 5 references
- [7] doi:10.26508/lsa.202201457
- SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis.Journal: Life science allianceIn common: mouse, 4 references
- [8] doi:10.1038/s41467-026-73545-8
- Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice.Journal: Nature communicationsIn common: other condition, mouse, 4 references
- [9] doi:10.1038/s41467-024-50095-5
- Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing.Journal: Nature communicationsIn common: other condition, mouse, 3 references
- [10] doi:10.1002/1873-3468.70303
- Organ-specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides.Journal: FEBS lettersIn common: other condition, mouse, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
